Latest Daiichi Sankyo News & Updates

See the latest news and media coverage for Daiichi Sankyo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Daiichi Sankyo

Global pharmaceutical company

daiichisankyo.com
Headquarters
Chuo-ku, Japan
Company type
Public company
Number of employees
10,000+
Industry
Pharmaceuticals

Last updated

Latest news about Daiichi Sankyo

In short: Daiichi Sankyo applied to expand Enhertu's Japanese use to uterine carcinosarcoma.

Company announcements

Daiichi Sankyo

Daiichi Sankyo Enhertu approved in China for adjuvant breast cancer treatment

Approval based on DESTINY-Breast05 results showing 53% reduced recurrence risk. It marks the fifth Enhertu approval in less than a year.

Unlock all announcements with a

Media coverage

Pharmaceutical Executive

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates...

FDA approves AstraZeneca and Daiichi Sankyo’s Datroway for first-line metastatic triple-negative bre...

Unlock all articles with a

Never miss news about Daiichi Sankyo

Track Daiichi Sankyo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.